Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation
Authors:
Open Access
- 2 January 2025
- journal article
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and challenging disease characterized by the deposition of misfolded transthyretin protein in the myocardial interstitium. Until recently, treatment options for ATTR-CM have been limited, with tafamidis emerging as the primary therapeutic agent targeting the stabilization of transthyretin tetramers to prevent amyloid fibril formation. However, advancements in understanding ATTR-CM's underlying mechanisms have led to developing novel therapeutic strategies to address various aspects of the disease process. This review explores the current landscape of therapeutic options for ATTR-CM. It encompasses strategies ranging from inhibiting TTR synthesis using RNA silencing methods such as small interfering RNA (e.g. HELIOS-B trial with vutrisiran) and antisense oligonucleotides (e.g. CARDIO-TTRansform trial with eplontersen) to gene-editing technologies like CRISPR/Cas9 (e.g. MAGNITUDE trial with NTLA-2001). Additionally, it explores TTR stabilization approaches beyond tafamidis, such as next-generation acoramidis, which showed success in the ATTRibute-CM trial. It also examines therapies promoting TTR degradation and removal, which includes the use of monoclonal antibodies (e.g. DepleTTR-CM with ALXN2220) and other compounds like doxycycline or epigallocatechin-3-gallate (a green tea component), which, despite long-standing recognition, remain underexplored. Novel approaches such as seeding inhibitors and molecular tweezers, which aim to inhibit TTR fibrilKeywords
This publication has 29 references indexed in Scilit:
- Stratifying Disease Progression in Patients With Cardiac ATTR AmyloidosisJACC, 2024
- Cardiac Amyloidosis Due to Transthyretin ProteinJAMA, 2024
- Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycansProtein Science, 2024
- Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathyHeart Failure Reviews, 2024
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac AmyloidosisJACC, 2023
- Therapeutic siRNA: State-of-the-Art and Future PerspectivesBioDrugs, 2022
- RNA-targeting and gene editing therapies for transthyretin amyloidosisNature Reviews Cardiology, 2022
- Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) AmyloidosisThe Journal of Clinical Pharmacology, 2019
- Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging SystemJACC, 2016
- Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils 1 1Edited by M. MoodyJournal of Molecular Biology, 2002